01—Abstract
Summary
Summary of the 10-K filed February 22, 2012. Cited figures are marked; the original filing is the authoritative source.
Incyte Corporation's 10-K for fiscal 2011 reports that its first commercial product, JAKAFI (ruxolitinib), received FDA approval on November 16, 2011 for intermediate or high-risk myelofibrosis and launched in the United States that month, with a 60-person specialty sales force and a wholesale acquisition cost of $7,000a for a 30-day supply.
Product revenue was only $2.0 millionb in 2011, while total revenues were $94.5 million, down from $169.9 million in 2010, as collaboration milestone recognition declined. Net loss widened to $186.5 million, or $1.49 per share, from $31.8 million, $0.26 per share, in 2010, and research and development expense rose to $178.7 million. The company had $277.6 million in cash, cash equivalents and marketable securities at year-end 2011, against $420.0 million of total consolidated debt, including $400.0 million of 4.75% convertible senior notes due 2015, and a stockholders' deficit of $227.1 million.
Management states that available capital is adequate for at least the next twelve months, though it expects to need additional financing and has relied on collaborations with Novartis, Eli Lilly and Pfizer. The investment case rests heavily on JAKAFI's commercial uptake, reimbursement and manufacturing, since the company relies on single third-party manufacturers and Chinese-sourced raw materials for the drug. The pipeline includes a global Phase III trial of ruxolitinib in polycythemia vera (SPA agreement in place, about 200 patients), a Phase II pancreatic cancer trial, and LY3009104 in Phase IIb for rheumatoid arthritis and psoriasis with results expected in 2012 for the RA trial.
Incyte has licensed rights to several compounds to partners, so future revenue depends on milestones and royalties, and the company states it has never paid dividends. The filing describes an operating-loss-driven company in transition from development to commercialization, with a limited history of product sales and significant dependence on JAKAFI's success.
02—Key points
Key Highlights
- JAKAFI (ruxolitinib) was FDA-approved on November 16, 2011 for intermediate or high-risk myelofibrosis and became commercially available in November 2011, marking Incyte's first U.S. product approval.
- Product revenues, net were $2.0 million in 2011, while total revenues fell to $94.5 million from $169.9 million in 2010, largely because 2010 included $102.0 million of collaboration milestones.
- Net loss was $186.5 million ($1.49 per share) in 2011, compared with $31.8 million ($0.26 per share) in 2010; research and development expense was $178.7 million.
- Cash, cash equivalents and marketable securities totaled $277.6 million at December 31, 2011, against total consolidated debt of $420.0 million and a stockholders' deficit of $227.1 million.
- The $400.0 million 4.75% convertible senior notes due 2015 carry annual interest of $19.0 million, and $19.0 million is held in escrow for interest payments through October 2012.
- JAKAFI's wholesale acquisition cost is $7,000 for a 30-day supply, and the company estimates 16,000 to 18,500 U.S. myelofibrosis patients, with 80% to 90% of them intermediate or high-risk.
- Pipeline includes a Phase III trial of ruxolitinib in advanced polycythemia vera (about 200 patients, SPA agreement) and LY3009104 in Phase IIb trials for rheumatoid arthritis and psoriasis, with Lilly's RA results expected in 2012.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2011filed February 22, 2012Financial Statements
FY2011 against FY2010
| Line item | FY2011FY2010 | Change |
|---|---|---|
| Revenue | $94.45M$169.88M | −44.4% |
| R&D Expenses | $178.71M$123.88M | +44.3% |
| SG&A Expenses | $58.22M$32.33M | +80.1% |
| Operating Expenses | $237.64M$155.83M | +52.5% |
| Operating Income | -$143.18M$14.05M | −1119.2% |
| Interest Expense | $43.82M$43.32M | +1.1% |
| Net Income | -$186.54M-$31.85M | −485.8% |
| EPS (Basic) | $-1.49$-0.26 | −473.1% |
| Shares Outstanding (Basic) | 125.36M121.63M | +3.1% |
| Shares Outstanding (Diluted) | 125.36M121.63M | +3.1% |
05—Questions
Frequently Asked Questions
What is the main driver of value for Incyte investors?
The filing identifies JAKAFI as the company's lead product and says the commercial success of JAKAFI in intermediate or high-risk myelofibrosis is the most important factor for future revenue and profitability. Product revenue was only $2.0 million in 2011, so sales ramp-up is the key metric to watch.
Does Incyte have enough cash to fund operations?
Management states that its cash, cash equivalents and marketable securities of $277.6 million will be adequate to satisfy capital needs for at least the next twelve months. It notes, however, that it expects to finance future cash needs through equity offerings, debt financings or collaborations, and that the 4.75% convertible notes and Pfizer notes create fixed obligations.
How does Incyte generate revenue beyond JAKAFI sales?
Contract revenues of $91.9 million in 2011 came from straight-line recognition of upfront fees under the Novartis and Lilly agreements, plus milestone payments of $25.0 million from Novartis. Future revenue depends on additional milestones and royalties from these partners, which the filing says may never materialize.
What are the main risks to JAKAFI's commercial launch?
The filing cites reliance on a limited number of specialty pharmacies, reimbursement from government and private payors, dependence on single-source third-party manufacturers and Chinese-sourced raw materials, and the need to maintain FDA approval. It also notes the company has no prior experience selling drug products.
Does Incyte pay dividends or face material legal proceedings?
Incyte has never declared or paid dividends and does not anticipate paying them in the foreseeable future. The filing states the company is not currently a party to any material legal proceedings.
06—Continue